Program Goals

Click here to register for this event

This program will acquaint urologists and related healthcare professionals with the use of FISH diagnostic and surveillance methods for detection and treatment of non-muscle invasive bladder cancer. Case presentations of clinical scenarios with interactive panel discussion will explore varying approaches to disease management.

Target Audience

This activity is designed to meet the educational needs of urologists and related healthcare professionals in the management of patients with bladder cancer.

  • Physicians: Urologists (Board Certified, Board Eligible, Fellow and Residents), Uropathologists, Uro-oncologists
  • Ancillary healthcare professionals: PAs, RNs, PhDs, research personnel, lab professionals

Educational Objectives

After completing this activity, the participant should be able to:

  1. Describe the scientific basis involved with urine FISH detection and management of bladder cancer.
  2. Review the working and performance characteristics of FISH in the management of bladder cancer.
  3. Explain how to best utilize recent scientific findings in urine diagnostics in the management of bladder cancer patients.


Michael A. O’Donnell, MD
Professor, Department of Urology
Chief, Urologic Oncology
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Kevin C. Halling, MD, PhD
Assistant Professor of Laboratory Medicine
Assistant Professor of Pathology
Co-Director, Molecular Genetics Laboratory
Mayo Clinic
Rochester, Minnesota
R. Jeffrey Karnes, MD
Assistant Professor of Urology
Mayo Clinic
Rochester, Minnesota


-  05 minutes: Welcome & Introduction
- 75 minutes: Case Studies & Discussion
- 10 minutes: Evaluation & Post-Test

Disclosure of Conflicts of Interests

Instructors, planners, managers and other individuals who are in a position to control the content of this activity are required to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty Disclosures

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this P.A.C.E.® accredited activity:

Name Type Commercial Supporter
Michael A. O'Donnell, MD
Abbott, Endo, Medical Enterprises,
Spectrum,  Viventia
Michael A. O'Donnell, MD
Grant / Research Support Alnylam Pharmaceuticals,
Kevin C. Halling, MD, PhD
Grant / Research Support Abbott
Kevin C. Halling, MD, PhD
Patent / Co-inventor
UroVysion™ probe, Abbott
R. Jeffrey Karnes, MD Nothing to Disclose
Nothing to disclose

Disclosure of Unlabeled Use / Investigational Use

In this activity, the following faculty discloses that they may discuss the unlabeled or investigational use of drugs, devices or procedures in their discussions regarding hepatitis therapy:

  • Michael A. O'Donnell< MD
  • Kevin C. Halling, MD, PhD
  • R. Jeffrey Karnes, MD

Planners and Managers

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this P.A.C.E.® accredited activity:

ASCLS - Name of Planner or Manager Reported Financial Relationship
Nothing to disclose Nothing to disclose
DGL - Name of Planner or Manager Reported Financial Relationship
LaRue Highsmith Nothing to disclose
(Spouse - no planning role) Admin: Abbott Laboratories

Credit Designation - Lab Professional, P.A.C.E.®

The American Society for Clinical Laboratory Science's Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program will provide 1.5 contact hour of credit.

How to Obtain P.A.C.E.® Credit


PACE_Logo.jpgViewers are expected to complete the presentation before attempting to submit contact information and the session evaluation. Successful completion will lead to the issuance of a certificate for 1.5 contact hour of P.A.C.E.® approved continuing education. To receive credit, the course must be completed by October 1, 2012.

Participation in this activity should be completed in approximately 1.5 hours. Please follow these steps in order to receive P.A.C.E.® credit for viewing the webcast:

  • Read all of the information above.
  • View the complete webcast program.
  • Click on the link to apply for P.A.C.E.® credit.
  • Complete the online registration (registration is free).
  • Complete the online test and/or evaluation. Participants must receive a test score of at least 70% and answer all evaluation questions to receive a certificate.
  • After successful completion of this process, you will be redirected to the ASCLS CE Organizer where you may create and print an official ASCLS P.A.C.E.® certificate based on your attendance and completion of this ASCLS-sponsored P.A.C.E.® approved learning activity.

Should you have any P.A.C.E.® questions regarding this activity, please contact:

1861 International Drive, Suite 200
Tysons Corner, VA 22102
Ph: 571-748-3776
Fx: 571-354-7576

Release and Expiration

Enduring Archive Release Date: October 1, 2011
Enduring Archive Expiration Date: October 1, 2012

Fee Information

There is no fee for this educational activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Dane Garvin Ltd. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Policy on Privacy and Confidentiality

Dane Garvin Ltd. protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. Dane Garvin Ltd. will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

Dane Garvin, Ltd. maintain physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Medium Used

This program has been made available online.

“Monitoring Bladder Cancer Using FISH Technology”

System Requirements

To view this educational activity you will need a web browser with Javascript and either Flash or HTML5 enabled.  Nearly all modern web browsers will work.


AMPlogo_transp_150.gif     This activity is co-sponsored by the Association for Molecular Pathology.

Commercial Support Statement

Abbott_logo.png    This activity is supported by an educational grant from Abbott Molecular.


Copyright © October 1, 2011 - October 1, 2012   Dane Garvin, Ltd.   All Rights Reserved. Permission for accreditation use granted to the American Society for Clinical Laboratory Science (ASCLS).